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Abstract 
Background: Glucagon-like peptide-1 (7–36) amide (GLP-1) protects against stunning and cumulative left ventricu-
lar dysfunction in humans. The mechanism remains uncertain but GLP-1 may act by opening mitochondrial K-ATP 
channels in a similar fashion to ischemic conditioning. We investigated whether blockade of K-ATP channels with 
glibenclamide abrogated the protective effect of GLP-1 in humans.
Methods: Thirty-two non-diabetic patients awaiting stenting of the left anterior descending artery (LAD) were allo-
cated into 4 groups (control, glibenclamide, GLP-1, and GLP-1 + glibenclamide). Glibenclamide was given orally prior 
to the procedure. A left ventricular conductance catheter recorded pressure–volume loops during a 1-min low-pres-
sure balloon occlusion (BO1) of the LAD. GLP-1 or saline was then infused for 30-min followed by a further 1-min bal-
loon occlusion (BO2). In a non-invasive study, 10 non-diabetic patients were randomized to receive two dobutamine 
stress echocardiograms (DSE) during GLP-1 infusion with or without oral glibenclamide pretreatment.
Results: GLP-1 prevented stunning even with glibenclamide pretreatment; the Δ % dP/dtmax 30-min post-BO1 nor-
malized to baseline after GLP-1: 0.3 ± 6.8 % (p = 0.02) and GLP-1 + glibenclamide: −0.8 ± 9.0 % (p = 0.04) compared 
to control: −11.5 ± 10.0 %. GLP-1 also reduced cumulative stunning after BO2: −12.8 ± 10.5 % (p = 0.02) as did 
GLP-1 + glibenclamide: −14.9 ± 9.2 % (p = 0.02) compared to control: −25.7 ± 9.6 %. Glibenclamide alone was no 
different to control. Glibenclamide pretreatment did not affect global or regional systolic function after GLP-1 at peak 
DSE stress (EF 74.6 ± 6.4 vs. 74.0 ± 8.0, p = 0.76) or recovery (EF 61.9 ± 5.7 vs. 61.4 ± 5.6, p = 0.74).
Conclusions: Glibenclamide pretreatment does not abrogate the protective effect of GLP-1 in human models of 
non-lethal myocardial ischemia.
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Background
Percutaneous coronary intervention (PCI) is the cor-
nerstone of treatment for acute myocardial infarc-
tion (AMI) but ischemia–reperfusion (IR) injury may 
account for up to 50  % of the final infarct size [1]. 
Adjunctive cardioprotective strategies to limit or pre-
vent IR injury are desperately needed [2]. One strategy is 
ischemic conditioning (IC) in which repeated episodes 
of brief ischemia applied to a tissue protect against 
larger ischemic insults both locally and in distant tissues 
[3–5]. IC mediates cardioprotection through the open-
ing of the mitochondrial K-ATP (mK-ATP) channel and 
closure of the mitochondrial permeability transition 
pore (mPTP) [6]. Blockade of mK-ATP with the sulfo-
nylurea glibenclamide (glyburide) has been shown to 
abolish IC in humans [7, 8]. Sulfonylureas are important 
medications for the treatment of diabetes mellitus but 
they may cause an increase in cardiovascular mortality, 
perhaps as a result of interfering with protection from 
ischemic conditioning [9].
IC has proved challenging to translate into patient 
benefit so other strategies have focused on pharmaco-
logical agents to limit IR injury [2]. One promising agent 
is Glucagon-like peptide-1 (7–36) amide (GLP-1), an 
incretin hormone with an insulinotropic action, released 
from the gut in response to a food bolus [10]. Exogenous 
GLP-1 receptor agonists and drugs that inhibit its break-
down are used to treat type 2 diabetes mellitus. A ben-
eficial off-target effect of GLP-1 is protection against IR 
injury [11–13]. GLP-1 abolishes PCI-induced left ven-
tricular (LV) stunning (supply ischemia) [14, 15] and 
improves LV function during dobutamine stress echocar-
diography (demand ischemia) [16]. Evidence from animal 
studies suggests that GLP-1 may act through similar sub-
cellular signaling pathways to IC [17, 18]. We sought to 
establish whether blockade of mK-ATP would abolish the 
cardioprotection conferred by GLP-1 in human studies of 
both demand and supply ischemia.
Methods
Study population
Patients were aged over 18  years old and able to give 
informed consent. They had proximal left anterior 
descending artery (LAD) disease requiring PCI (sup-
ply protocol) or any coronary artery disease requiring 
revascularization (demand protocol). Patients were not 
enrolled in both studies. Exclusion criteria were pres-
ence of diabetes mellitus, use of nicorandil or ranolazine, 
a serum creatinine  >200  μmol/l, presence of a cardiac 
pacemaker, valvular heart disease, impaired left ventricu-
lar systolic function, recent myocardial infarction or life 
expectancy less than 6-months.
Ethics, consent and permissions
Both protocols were approved by the local ethics com-
mittee (14/EE/0056 and 08/H0304/68) and informed, 
written consent was obtained from all participants 
before enrolment. Studies were carried out in accord-
ance with institutional guidelines. The studies were reg-
istered on clinicaltrials.gov (NCT02128022) and ISRCTN 
(ISRCTN69686930) and were performed in accordance 
with the Declaration of Helsinki.
Supply ischemia protocol
A timeline for this protocol is shown in Fig.  1. Patients 
were fasted for 6 h prior to the procedure and received 
standard dual antiplatelet loading with aspirin and clopi-
dogrel. Patients were allocated to one of four groups: 
saline control, GLP-1 alone, saline with glibenclamide 
and GLP-1 with glibenclamide. Patients received glib-
enclamide 5 mg orally at least 60 min prior to their PCI 
procedure and had a dextrose 20 % infusion initiated at 
1.5 mg/kg/min to minimize the risk of hypoglycemia. In 
mechanistic studies an oral dose of 5 mg was sufficient to 
inhibit IC in humans [19].
Sheaths were placed in the right femoral artery, right 
radial artery and right femoral vein. Between 70 and 
100 U/kg of unfractionated heparin was administered 
to maintain an activated coagulation time of  >250  s 
throughout the procedure. An 8-electrode 7F conduct-
ance catheter (Millar Instruments, Houston, USA) was 
connected to an MPVS Ultra (Millar Instruments, Hou-
ston, USA) signal-conditioning unit in series with an 
ADInstruments PowerLab 16/30 Series (ADInstruments, 
New South Wales, Australia) 16-channel amplifier. It was 
positioned along the longitudinal ventricular axis with 
the tip at the apex of the LV (Fig.  2). The conductance 
catheter was calibrated and corrected for parallel con-
ductance [14, 20] as described in Additional file 1.
The left coronary ostium was intubated with a guide 
catheter and the lesion was crossed with a coronary guide 
wire. Baseline pressure–volume loops were recorded 
from the conductance catheter after the lesion was 
crossed (BL1) during a breath-hold in mid-expiration. 
Similarly, pressure–volume loops were recorded at the 
end of a 1-min low-pressure (<4 atmospheres) coronary 
balloon inflation (BO1) within the lesion. Contrast was 
injected during balloon inflation to confirm coronary 
occlusion.
Patients randomized to receive GLP-1 then received 
an intravenous infusion of GLP-1 at 1.2  pmol/kg/min 
started immediately after balloon deflation. This dose 
was selected as it had been effective in inducing cardio-
protection in previous studies, with minimal side-effects 
[14]. Those patients in the control and glibenclamide only 
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groups received an infusion of normal saline at the same 
rate. After 30-min, further pressure–volume loops were 
collected (BL2) followed by recordings after a further 
1-min balloon occlusion (BO2). Patients then received 
conventional coronary angioplasty and stenting of the 
lesion at the discretion of the treating physician. One-
minute balloon occlusions are long enough to induce 
ischemic dysfunction and stunning of the myocardium 
but will not activate the protective effect of ischemic con-
ditioning [21].
Pressure–volume loop analysis
Conductance catheter data analysis was performed 
offline using LabChart (AdInstruments, New South 
Wales, Australia), by investigators blinded to treatment 
allocation. Five cardiac cycles recorded at each time-
point (BL1, BO1, BL2, BO2) were sampled (Fig.  2) and 
used to determine systolic parameters: dP/dtmax (maxi-
mum rate of isovolumic pressure increase), stroke vol-
ume and ejection fraction and diastolic parameters: dP/
dtmin (maximum rate of isovolumic pressure decline) and 
Tau (time constant of isovolumic pressure decline). Tau 
is calculated from the conductance catheter-derived Pt 
(time constant of pressure relaxation) which is measured 
from the time of peak rate of pressure decline (dP/dtmin) 
to 5 mmHg above end-diastolic pressure.
Demand ischemia protocol
Patients underwent two dobutamine stress echocardio-
grams (DSE) in randomly allocated order, performed at 
least 1 week apart. Patients attended in the morning fol-
lowing an overnight fast and received a GLP-1 infusion 
with or without oral glibenclamide 5  mg administered 
60-min prior to the GLP-1 infusion. GLP-1 was started at 
1.2 pmol/kg/min followed by dobutamine administration 
15  min later. An intravenous infusion of 20  % dextrose 
started at 1.5 mg/kg/min was given during both DSE to 
minimize the risk of glibenclamide-induced hypoglycae-
mia. Each patient acted as their own control. Intrave-
nous dobutamine infusion was incrementally increased 
Fig. 1 Structure of supply and demand protocols. a Timeline for the supply ischemia protocol. Blood tests were taken immediately before the two 
balloon occlusions. GLP-1 was administered until BO2 was complete. b The study timeline for the demand ischemia protocol
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from 10 μg/kg/min to 20, 30 and 40 μg/kg/min at 3-min 
intervals. Up to 2  mg of intravenous atropine could be 
given if necessary to reach the target heart rate. Both 
GLP-1 and dextrose infusions continued throughout the 
protocol until recovery was complete (Fig.  1). Criteria 
for stopping included, achievement of target heart rate 
(220 – Age * 0.85 BPM), angina, ischemic ECG changes 
(ST depression or elevation greater than 2  mm), rise in 
systolic blood pressure to  >240  mmHg, fall in systolic 
blood pressure to <100 mmHg or severe arrhythmia.
Transthoracic echocardiographic analysis
Two-dimensional transthoracic tissue Doppler imag-
ing (TDI) was performed in the left recumbent position 
at rest, peak stress and 30-min recovery. Images were 
recorded in 2, 3 and 4 chamber apical views allowing a 
12-segment model (apical and mid segments) of regional 
wall motion to be assessed. Segments were classified as 
ischemic or non-ischemic according to whether or not 
they were subtended by a coronary stenosis  >70  % by 
Quantitative Coronary Angiographic (QCA) analysis, 
Fig. 2 Examples of methodology. a Conductance catheter in position in the left ventricle during an injection of contrast into the left coronary 
artery. The proximal LAD lesion can be seen. b Pressure–volume loops generated at baseline (blue) and during occlusion of the LAD (red). c Dobu-
tamine stress echo at peak stress. Strain rate is shown to the right with the peak systolic strain rate the most negative point between aortic valve 
opening and closure
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as validated by Baptista et  al. [22]. Relevant ischemic-
segments were analyzed offline to determine the sys-
tolic tissue velocity (Vs), strain index (SI), and strain rate 
index (SRI) by a clinician blinded to treatment allocation 
(Fig. 2). Global left ventricular function was calculated by 
ejection fraction (EF) using Simpson’s Biplane method 
and mitral annular systolic velocity (MASV) aver-
aged from six sites. Inter-observer variability and intra-
observer variability were assessed using images from 
three randomly selected patients. This was expressed 
as an Interclass Correlation Coefficient (ICC) with 95 % 
confidence interval [23].
Biochemistry
During the supply ischemia protocol venous blood was 
sampled at baseline and immediately prior to BO1 and 
BO2. In the demand ischemia protocol venous blood 
was sampled prior to starting dextrose, GLP-1 and dobu-
tamine infusions, at peak stress and at 30-minute recov-
ery (Fig. 1).
GLP-1 (7–36) amide, free fatty acid, insulin and glucose 
levels were assayed. Samples for GLP-1 were drawn into 
tubes containing dipeptidyl peptidase 4 (DPP4) inhibi-
tor (Millipore, UK) to prevent degradation and measured 
using a commercially available assay (Meso Scale Discov-
ery, MD, USA). Glucose samples were measured by YSI 
2300 STAT Plus analyzer (YSI Life Sciences, UK).
Statistical analysis
In the supply protocol a power calculation was carried 
out based on previous work by our group [14]. Analy-
sis of non-diabetic patients who had previously received 
saline or GLP-1 infusion after a balloon occlusion in a 
similar protocol to this study had a delta dP/dtmax at BL2 
of −13.4 ± 9.3 % and −1.4 ± 8.5 % respectively. We esti-
mated that to detect a difference of 8 % at BL2 (α = 0.05, 
β = 0.2) a sample size of 8 per group was required.
In the demand ischemia protocol, previous data 
has shown that a GLP-1 infusion caused an addi-
tional increase in ejection fraction at peak stress from 
70.8 ±  4.96 to 77.0 ±  4.39 % in a paired study [16]. We 
estimated that to detect a 5 % change in ejection fraction a 
sample size of 7 patients were needed (α = 0.05, β = 0.2).
All analyses were pre-specified. Continuous data are 
presented as mean ± SD unless otherwise stated. Paired 
and unpaired Student’s t test or Mann–Whitney U test 
were used to compare continuous variables as appropri-
ate, and Chi Square test was used for categorical vari-
ables. In the supply ischemia study, 4-way comparisons 
between groups were carried out with a one-way inde-
pendent ANOVA. A p value of <0.05 was deemed statis-
tically significant.
Results
Supply ischemia protocol
Thirty-three patients were recruited into the 4 groups 
detailed above (Additional file 1: Figure S1). In one case 
the operator was unable to cross the aortic valve with 
the conductance catheter and this patient was excluded. 
Demographic details for the groups are summarized in 
Additional file  1: Table  S1 and confirm that they were 
well matched.
Biochemistry data is summarized in Table  1. Levels 
of plasma GLP-1 (7–36) amide were below 3.0 pg/ml at 
baseline and during BO1 confirming no significant dif-
ference between groups. Plasma levels of GLP-1 (7–36) 
amide rose at BO2 in groups treated with GLP-1 com-
pared with those administered only saline, with no sig-
nificant difference between the GLP-1-treated groups 
(p = 0.41). Plasma levels of insulin were significantly ele-
vated at BO2 in patients treated with glibenclamide and 
the combination of GLP-1 and glibenclamide caused an 
even greater rise although the response was highly vari-
able between individuals. Patients treated with glibencla-
mide also had significant suppression of free fatty acids at 
BO1 and BO2. Plasma glucose levels were higher at BO2 
in glibenclamide treated groups, compared with control, 
despite the rise in insulin levels, reflecting the co-admin-
istration of dextrose alongside glibenclamide.
There were no significant differences between the base-
line hemodynamic parameters of groups (Additional 
file  1: Table  S2). Table  2 describes how parameters of 
systolic and diastolic function change during the supply 
ischemia protocol for each group. All groups suffered 
ischemic LV dysfunction during BO1 compared to BL1, 
with a significant deterioration in all measured param-
eters of systolic and diastolic function. There was no sig-
nificant difference between any groups at BO1. At BL2 
there was recovery of dP/dtmax and dP/dtmin to BL1 levels 
in both GLP-1 treated groups. There was impaired recov-
ery of dP/dtmax and dP/dtmin in control and glibenclamide 
only groups with significant stunning compared with 
BL1. Glibenclamide had a neutral effect on systolic and 
diastolic function during balloon occlusion and recovery.
Cumulative stunning after the second balloon occlu-
sion was only observed in groups not receiving GLP-1; 
systolic and diastolic function did not deteriorate below 
the level observed at BO1 in GLP-1 treated groups. 
Change in dP/dtmax (Fig.  3) and dP/dtmin (Fig.  4) are 
shown for each group at the specified time points. GLP-1 
infusion also improved EF at BL2 and BO2 compared 
to control although this was only statistically significant 
at BO2. Tau appeared to improve with GLP-1 but this 
was not statistically significant. There was no significant 
change in heart rate (p = 0.14) or mean arterial pressure 
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(p = 0.67) between balloon occlusions, or between indi-
vidual groups.
Demand ischemia protocol
Ten patients were recruited into the demand ischemia 
protocol. Two patients did not go on to have both DSE 
(one patient withdrew and one needed urgent revascular-
ization prior to second DSE). Detailed demographic data 
are summarized in the Additional file 1: Table S3.
Overall there were no significant differences in hemo-
dynamic parameters between the DSE. Importantly, 
GLP-1 infusion did not increase heart rate during the 
15 min prior to the DSE in the GLP-1 only DSE (57 ± 3.8 
vs. 58 ±  3.9, p =  0.44). There was no significant differ-
ence in the RPP at peak stress between the DSE. These 
data are summarized in Additional file 1: Table S4.
There was a rise in GLP-1 levels at peak stress during 
both DSE of over 50-fold compared with pre-DSE levels. 
Insulin levels rose in both DSE but were twice as high for 
the GLP-1 + glibenclamide group (p = 0.04). There was 
increased suppression of free fatty acids with GLP + glib-
enclamide. Biochemistry data for the demand ischemia 
protocol are summarized in Additional file 1: Table S5.
There was no difference in global indices of systolic 
function between the paired DSE at either peak stress or 
recovery, indicating that glibenclamide did not attenu-
ate the effect of GLP-1 (Table 3). Regional tissue Doppler 
indices were also unchanged when ischemic segments 
alone, and all segments together were analyzed (Addi-
tional file 1: Table S6). Changes in the global and regional 
tissue Doppler indices are shown in Fig.  5. The ICC for 
inter- and intra-observer variability respectively was 
0.899 (0.850–0.931) and 0.922 (0.863–0.975) for Vs; 
0.802 (0.698–0.873) and 0.831 (0.748–0.886) for SI; 0.817 
(0.637–0.908) and 0.844 (0.691–0.901) for SRI.
Discussion
In both the supply and demand ischemia protocols, 
addition of glibenclamide did not affect GLP-1 cardio-
protection; GLP-1 protection against both ischemic left 
ventricular dysfunction and stunning remained. The 
implication of this study is that GLP-1 cardioprotection 
is not mediated through mK-ATP dependent pathways. 
Similar metabolic profiles (between glibenclamide-
treated groups) ruled-out a metabolic explanation for 
the cardioprotection observed. Only the presence or 
Table 1 Metabolic changes during supply ischemia protocol
* p value compared with control group
Baseline Balloon occlusion 1 (BO1) Balloon occlusion 2 (BO2)
p value* p value* p value*
GLP-1 (7–36) amide, pg/ml
 Control 2.9 ± 3.57 – 3.6 ± 4.13 – 2.9 ± 1.84 –
 GLP-1 only 2.8 ± 1.43 0.51 2.5 ± 2.04 0.49 87.5 ± 37.1 <0.001
 Glibenclamide only 1.9 ± 1.66 0.46 1.1 ± 0.77 0.11 1.3 ± 0.54 0.07
 GLP-1 glibenclamide 2.2 ± 0.59 0.57 2.3 ± 1.32 0.37 78.9 ± 31.1 <0.001
Insulin, pmol/L
 Control 79 ± 26 – 59 ± 29 – 58 ± 29 –
 GLP-1 only 77 ± 52 0.91 63 ± 85 0.82 95 ± 64 0.16
 Glibenclamide only 103 ± 93 0.51 292 ± 245 0.02 382 ± 297 0.02
 GLP-1 glibenclamide 90 ± 51 0.63 412 ± 244 <0.01 1133 ± 1089 0.03
Glucose, mmol/l
 Control 5.1 ± 0.3 – 5.3 ± 0.3 – 5.4 ± 0.4 –
 GLP-1 only 5.0 ± 0.3 0.83 5.0 ± 0.3 0.51 4.7 ± 0.3 0.20
 Glibenclamide only 5.3 ± 0.3 0.66 6.3 ± 0.4 0.06 6.8 ± 0.4 0.02
 GLP-1 glibenclamide 5.5 ± 0.3 0.44 5.9 ± 0.4 0.27 5.9 ± 0.7 0.45
Free fatty acids, μmol/L
 Control 371 ± 364 – 1399 ± 973 – 1050 ± 637 –
 GLP-1 only 473 ± 367 0.57 1213 ± 897 0.69 917 ± 516 0.64
 Glibenclamide only 358 ± 201 0.93 633 ± 434 0.06 439 ± 248 0.02
 GLP-1 glibenclamide 356 ± 183 0.91 846 ± 490 0.16 503 ± 307 0.04
Dextrose infusion, mg kg−1 min−1
 Glibenclamide only – – 1.69 ± 0.53 – 1.69 ± 0.53 –
 GLP-1 glibenclamide – – 2.25 ± 1.6 – 2.44 ± 1.59 –
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absence of GLP-1 appeared to be associated with a pro-
tective effect and this was independent of both mK-ATP 
blockade and changes in myocardial substrate and insulin 
levels.
IC acts via mK-ATP-dependent subcellular signaling 
pathway that is activated by up-stream RISK/SAFE path-
ways of cardioprotection [11, 18]. IC protection from 
non-lethal endothelial IR injury has been shown to be 
K-ATP dependent in humans. This protection is blocked 
with glibenclamide [8]. Although IC has not been shown 
to protect against stunning or ischemic dysfunction in 
humans [24], GLP-1 does protect the LV against this 
model of non-lethal IR injury, as confirmed in this study. 
The current study also shows that co-administration of 
glibenclamide with GLP-1 does not affect GLP-1 cardio-
protection. Therefore cardioprotection against non-lethal 
IR injury by GLP-1 is not mediated through mK-ATP 
dependent subcellular signaling pathways in humans. 
This is surprising since a number of other studies sug-
gest K-ATP dependent signaling pathways mediate the 
actions of GLP-1 on the vasculature. K-ATP channels are 
involved in GLP-1 dependent relaxation of the aorta in a 
rat model, and endothelial function in human forearms 
[17, 25]. Animal studies have shown that phosphoino-
sitol-3 kinase (PI3K) and Akt are consistently activated 
during treatment with GLP-1 [11, 18, 26]. Our study sug-
gests that either human GLP-1 cardioprotection is medi-
ated through an alternative pathway, or that PI3K-Akt 
signaling acts through an alternative mechanism to pro-
tect against myocardial stunning and ischemic dysfunc-
tion. There is considerable cross-talk in the RISK/SAFE 
pathways and it may be that these kinases are acting on 
an alternative distal target [27]. Since evidence suggests 
that the known GLP-1 receptor is not present on the 
human ventricular cardiomyocyte [28], GLP-1 may act 
remote to the myocardium or by binding an as yet uni-
dentified receptor.
In the supply protocol both glibenclamide alone and 
GLP-1 alone produced a rise in insulin levels and a fall 
in free fatty acids compared to saline control. However, 
Table 2 Change in parameters of systolic and diastolic function (compared to BL1) in supply ischemia protocol
* p value compared to BL1 for each group
Baseline 1 (BL1) Balloon occlusion 1 (BO1) Baseline 2 (BL2) Balloon occlusion 2 (BO2)
% Δ % p value* Δ % p value* Δ % p 
value*
dP/dtmax
 Control 100 −15.4 ± 13.6 0.012 −11.5 ± 10.0 <0.01 −25.7 ± 9.6 <0.001
 GLP-1 only 100 −16.1 ± 10.2 <0.01 −0.3 ± 6.8 0.92 −12.8 ± 10.5 0.011
 Glibenclamide only 100 −16.1 ± 14.4 0.011 −10.0 ± 4.7 <0.01 −21.7 ± 10.5 <0.01
 GLP-1 glibenclamide 100 −13.5 ± 9.7 <0.01 −0.8 ± 9.0 0.82 −14.9 ± 9.2 <0.01
Ejection fraction
 Control 100 −18.3 ± 14.1 0.01 −13.8 ± 15.5 0.03 −31.1 ± 16.0 <0.001
 GLP-1 only 100 −17.9 ± 13.3 0.01 −8.4 ± 12.7 0.10 −11.7 ± 17.8 0.10
 Glibenclamide only 100 −17.2 ± 13.4 0.01 −12.7 ± 19.6 0.14 −26.9 ± 14.2 <0.001
 GLP-1 glibenclamide 100 −16.9 ± 13.8 0.01 −8.4 ± 4.8 <0.01 −13.1 ± 9.5 <0.01
Stroke volume
 Control 100 −19.6 ± 18.1 0.03 −16.4 ± 16.3 0.02 −31.2 ± 16.6 <0.001
 GLP-1 only 100 −19.8 ± 17.5 0.01 −5.8 ± 27.1 0.56 −12.6 ± 28.8 0.26
 Glibenclamide only 100 −16.8 ± 17.8 0.08 −12.6 ± 18.2 0.12 −23.2 ± 22.1 0.04
 GLP-1 glibenclamide 100 −14.8 ± 11.1 0.01 −0.2 ± 7.3 0.96 −5.6 ± 4.4 0.03
dP/dtmin
 Control 100 −25.1 ± 14.7 <0.01 −10.9 ± 4.7 <0.001 −33.3 ± 8.6 <0.001
 GLP-1 only 100 −21.3 ± 8.3 <0.001 +5.0 ± 11.6 0.26 −21.3 ± 8.7 0.04
 Glibenclamide only 100 −26.4 ± 14.3 <0.001 −7.1 ± 12.5 0.17 −28.6 ± 13.1 <0.001
 GLP-1 glibenclamide 100 −19.6 ± 6.1 <0.001 +2.9 ± 13.0 0.55 −14.3 ± 13.6 0.02
Tau
 Control 100 +34.7 ± 16.9 <0.01 +12.7 ± 7.8 <0.01 +46.4 ± 15.4 <0.001
 GLP-1 only 100 +27.3 ± 11.6 <0.001 +8.0 ± 18.6 0.26 +31.0 ± 36.7 0.05
 Glibenclamide only 100 +30.5 ± 25.8 <0.01 +13.1 ± 19.9 0.14 +36.2 ± 26.3 <0.001
 GLP-1 glibenclamide 100 +31.3 ± 27.2 <0.001 +5.5 ± 10.2 0.17 32.5 ± 13.2 <0.001
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only GLP-1 had a cardioprotective effect. Glibenclamide 
only produced changes in metabolic parameters without 
an observed difference in the function of the ventricle 
compared to control—this suggests that the metabolic 
effect of glibenclamide does not lead to alteration in car-
diac function in this model. The combination of GLP-1 
and glibenclamide produced even greater hyperinsu-
linemia but offered no additional protection beyond 
that of GLP-1 alone. Insulin levels with glibenclamide 
were similar to those observed during hyperinsuline-
mic clamp studies published by our group, which also 
showed a neutral effect of insulin on myocardial perfor-
mance during ischemia [29]. It has been suggested that 
the mechanism for GLP-1 cardioprotection is a switch 
in cardiomyocyte metabolism towards more energy effi-
cient myocardial glucose utilization [30]. Glibenclamide 
is insulinotropic through blockade of K-ATP on the pan-
creatic beta cell. The metabolic environment created with 
addition of glibenclamide and dextrose (increased avail-
ability of glucose, reduced availability of fatty acids and 
increased cellular uptake of glucose driven by hyperinsu-
linemia) should promote increased myocardial glucose 
utilization. However this environment did not result in 
cardioprotection without GLP-1, nor did it enhance car-
dioprotection beyond giving GLP-1 alone. These find-
ings are consistent with our earlier human work, which 
did not detect a change in transmyocardial substrate uti-
lization after GLP-1 infusion [15]. Taken as a whole, it 
seems unlikely that GLP-1 cardioprotection is mediated 
Fig. 3 Systolic function (ΔdP/dtmax) in supply ischemia protocol. 
Mean ± SEM. There were no statistically significant differences 
between groups at BO1. At BL2, dP/dtmax for GLP-1 was significantly 
improved compared to control (p = 0.02) and compared to gliben-
clamide alone (p < 0.01). This difference was maintained for compari-
son with control at BO2 (p = 0.02) and was numerically better than 
glibenclamide at BO2 (p = 0.12). dP/dtmax for GLP-1 + glibenclamide 
was significantly improved at BL2 compared to control (p = 0.02) and 
glibenclamide alone (p = 0.03). Again this difference was maintained 
for comparison with control at BO2 (p = 0.02) and trended towards 
improvement for glibenclamide alone at BO2 (p = 0.14). There was 
no statistically significant difference between GLP-1 treated groups, 
nor any difference between the control and glibenclamide only 
groups, at any timepoint
Fig. 4 Diastolic function (ΔdP/dtmin) in supply ischemia protocol. 
Mean ± SEM. There were no statistically significant differences 
between groups at BO1. At BL2, dP/dtmin for GLP-1 was significantly 
improved compared to control (p < 0.01) and numerically better 
than glibenclamide alone (p = 0.07). The difference between GLP-1 
vs. control was maintained at BO2 (p = 0.01). At BL2, dP/dtmin for 
GLP-1 + glibenclamide was again significantly improved compared 
to control (p < 0.01), and numerically better than glibenclamide alone 
(p = 0.15). These differences persisted for BO2 (p < 0.01 and 0.06 
respectively). There was no statistically significant difference between 
GLP-1 treated groups, nor any difference between the control and 
glibenclamide only groups, at any timepoint
Table 3 Change in  parameters of  global systolic function, 
and ischemic regional segments in demand ischemia pro-
tocol
GLP-1 only GLP-1 glibenclamide p value
Ejection fraction (%)
 Baseline 62.4 ± 8.4 63.1 ± 8.5 0.45
 Peak stress 74.6 ± 6.4 74.0 ± 8.1 0.76
 Recovery 61.9 ± 5.7 61.4 ± 5.6 0.74
MASV, cm/s
 Baseline 5.47 ± 1.79 5.51 ± 1.78 0.82
 Peak stress 11.40 ± 2.69 11.06 ± 2.80 0.24
 Recovery 5.70 ± 1.99 5.62 ± 1.75 0.51
Peak systolic velocity (Vs), cm/s
 Baseline 3.76 ± 1.89 3.92 ± 2.07 0.38
 Peak stress 9.86 ± 3.08 9.59 ± 2.81 0.18
 Recovery 3.95 ± 1.95 4.04 ± 1.56 0.98
Strain index (SI), %
 Baseline −15.3 ± 5.83 −15.1 ± 5.30 0.68
 Peak stress −15.5 ± 5.52 −15.6 ± 6.09 0.92
 Recovery −14.8 ± 5.35 −15.3 ± 6.21 0.48
Strain rate index (SRI), s-1
 Baseline −1.19 ± 0.74 −1.25 ± 0.51 0.29
 Peak stress −2.68 ± 1.69 −2.79 ± 1.17 0.65
 Recovery −1.24 ± 0.92 −1.25 ± 0.69 0.71
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Fig. 5 Systolic function in demand ischemia protocol. Mean ± SEM. Changes in global and regional systolic function at baseline, peak stress and 
30-min recovery. There are no statistically significant differences between the two studies at any timepoint. a Ejection fraction. b Mitral annular 
systolic velocity. c Peak systolic tissue velocity (Vs). d Peak systolic strain (SI). e Peak systolic strain rate (SRI)
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by straight-forward metabolic switching toward glucose 
metabolism or by change in insulin levels.
Studies have suggested that, in the human heart, the 
GLP-1 receptor is only present in the sinoatrial node 
[28]. GLP-1 receptor agonists such as Exenatide have 
been shown to increase heart rate [31]. In this study, the 
GLP-1 infusion did not affect heart rate. Since GLP-1 
did not affect heart rate, or afterload and the peak rate 
pressure product achieved, there was no evidence from 
this study that GLP-1 protection was mediated through 
an effect on the peripheral vasculature reducing cardiac 
workload. Further work to confirm this is needed.
The mechanism underlying GLP-1 cardioprotection 
in non-lethal IR injury remains speculative. Animal evi-
dence of mK-ATP dependent protection may still be 
applicable to lethal IR injury in humans. Alternatively, 
mK-ATP independent aspects of subcellular pro-survival 
kinase pathways may be involved in GLP-1 cardioprotec-
tion. Studies have suggested that adenosine may medi-
ate some of the observed GLP-1 effects [32]. Adenosine 
released from remote endothelial cells in response to 
GLP-1 receptor binding may elicit an inotropic effect by 
inducing hyperemia, or alternatively by a direct protec-
tive effects on cardiomyocytes [33]. Evidence of effects 
independent of the known GLP-1 receptor pathway have 
also been described [18, 34, 35] and GLP-1 may activate 
as yet unknown subcellular signaling pathways to con-
fer protection. The protection offered involved native 
GLP-1 rather than a stable GLP-1 receptor agonist such 
as Exenatide. This may mean that breakdown products 
such as GLP-1 (9–36) amide may be responsible for some 
of the observed cardioprotection. GLP-1 (9–36) has been 
implicated in cardioprotection in some animal studies 
[34, 35]. A number of other protective effects of GLP-1 
have been explored. These include effects on platelet 
aggregation and thrombosis [36], and anti-inflammatory 
effects [37]. Whilst these effects may be important in 
protection against, and recovery from myocardial infarc-
tion, they are unlikely to explain the protection conferred 
against myocardial stunning.
Limitations
The study does not present direct evidence of blockade of 
the cardiomyocyte mK-ATP channel. This was assumed 
on the basis of previous studies [19]. It may also be 
inferred in this study as the insulinotropic effect of glib-
enclamide on the pancreatic beta cell (which was seen in 
the biochemical results) is dependent on sarcoplasmic 
K-ATP blockade [38]. This insulinotropic effect of gliben-
clamide necessitated the co-administration of dextrose to 
prevent hypoglycemia. Whilst the analyses suggest that 
this has not affected our conclusions, it is not possible to 
completely exclude some confounding effect.
The supply ischemia protocol did not measure load-
independent indices of ventricular function such as the 
end-systolic pressure volume relationship (Ees) due to 
the difficulty of simultaneously recording a family of 
pressure–volume loops during preload reduction (IVC 
balloon occlusion) whilst also balloon occluding the 
coronary artery. However, blood pressure and heart rate 
remained constant during the procedure allowing valid 
comparison of the load-dependent parameters studied. 
Whilst it would also have been statistically preferable to 
enroll a larger number of patients, ethical and practical 
considerations limited numbers to those specified in the 
power calculation.
In the demand ischemia protocol it would have been 
preferable to perform prospectively recruited saline 
and glibenclamide only DSEs to control comprehen-
sively. This was not possible for both ethical and practi-
cal reasons. We instead relied upon our historic control 
data using the same protocol, which has demonstrated 
that GLP-1 augments myocardial performance during 
demand ischemia [16].
Conclusion
The cardioprotective effect of GLP-1 (7–36) amide in 
non-lethal IR ventricular injury does not appear to be 
mediated through an mK-ATP dependent pathway. 
Changes in myocyte substrate utilization and workload 
after GLP-1 also fail to explain the protection observed. 
Future mechanistic studies need to consider alternative 
mechanisms to explain the beneficial effect of GLP-1.
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